

Efflux Transporters as a Novel Herbivore Countermechanism to Plant Chemical Defenses

Jennifer S. Sorensen · M. Denise Dearing

Received: 25 October 2005 / Revised: 12 December 2005 /

Accepted: 23 January 2006

© Springer Science + Business Media, Inc. 2006

Abstract The recent discovery of efflux transporters in the gut has revolutionized our understanding of the absorption and bioavailability of pharmaceuticals and other xenobiotics in humans. Despite the celebrity of efflux transporters in the areas of pharmacology and medicine, their significance is only beginning to be realized in the area of plant–herbivore interactions. This review integrates reports on the importance of gut efflux transporters to diet selection by herbivores. The diets of herbivores are laden with toxic plant secondary metabolites (PSMs) that until recently were thought to be processed almost exclusively by detoxification enzymes in the liver. We describe how efflux transporters in the gut may play a critical role in regulating the absorption of PSMs in herbivores and dictating diet selection. Recent studies suggest that the role of efflux transporters in mediating diet selection in herbivores may be as critical as detoxification enzymes. In addition to diet selection, gut efflux transporters have implications for other aspects of plant–animal interactions. They may be significant components of the evolutionary arms race that influences chemical diversity in plants. Furthermore, in agricultural systems, gut efflux transporters may play an important role in the effectiveness of pesticides. This synthesis paper introduces a new direction in plant–herbivore interactions by providing a complementary mechanism, regulated absorption, to detoxification that may define tolerance to PSMs by herbivores.

Keywords Herbivores · Plant secondary metabolites · Regulated absorption · P-glycoprotein · Mammals · Efflux transporters · Diet selection · Herbivore tolerance · Transporter proteins

J. S. Sorensen (✉) · M. D. Dearing
Department of Biology,
University of Utah, Salt Lake City, UT 84112, USA
e-mail: jssorensen4b@yahoo.com

J. S. Sorensen
NPS Pharmaceuticals, Salt Lake City, UT 84108, USA

Introduction

Two central foci in plant–herbivore interactions have been identified to explain the diversity of plant chemical defenses as well as the variation in herbivore tolerance to defenses. Much progress has been made in identifying and quantifying plant secondary metabolites (PSMs), as well as understanding their influence on herbivore feeding (Freeland and Janzen, 1974; Palo and Robbins, 1991; Rosenthal and Berenbaum, 1992; Cheeke, 1998; Foley et al., 1999). Diversity in PSMs has been attributed to the need of plants to defend themselves against a wide range of herbivores and pathogens (Berenbaum et al., 1991; Fritz and Simms, 1992; Berenbaum, 1995, 1999). In contrast, relatively little progress has been made with respect to the other central goal, i.e., explaining the variation in tolerance to PSMs by herbivores. Variation in detoxification capabilities has long been suggested as the underlying mechanism responsible for differential tolerances to PSMs among herbivores (Freeland and Janzen, 1974; Foley et al., 1999; Pass et al., 2001; Karban and Agrawal, 2002; Li et al., 2004). However, individuals and species with the highest PSM tolerance do not always have the highest activity levels of detoxification enzymes (Neal, 1987) or the highest rates of PSM elimination. For example, *Neotoma stephensi*, a juniper specialist, can tolerate more juniper and PSMs in juniper than its generalist counterpart, *N. albigula* (Sorensen et al., 2005), but it does not have a faster rate of juniper PSM elimination from the blood (Sorensen and Dearing, 2003).

We propose that, in addition to enzymatic detoxification, variation in mechanisms that regulate absorption of PSMs in the intestine may further explain the variation in herbivore tolerance to PSMs. Although the importance of PSM absorption in herbivores is not a new concept, previously proposed mechanisms have focused on passive barriers in the gut such as peritrophic membranes (PMs) (Lehane, 1997; Barbehenn, 2001). In this work, we argue that in addition to passive barriers, herbivores can actively transport PSMs out of enterocytes and back into the lumen of the gut, limiting PSM absorption. We refer to this process and its predicted influence on the foraging behavior of herbivores as the “regulated absorption model.” We identify a plausible mechanism for regulated absorption and provide evidence that this mechanism can influence PSM tolerance in herbivores. In addition, we propose that regulated absorption of PSMs may further our understanding of chemical diversity in plants. Throughout, we provide several testable hypotheses regarding the role that regulated absorption plays in influencing the interactions between PSMs and herbivores. This synthesis paper introduces ecologists to a new direction in plant–herbivore interactions by providing a complementary mechanism, regulated absorption, to detoxification that may define tolerance to plant secondary metabolites by herbivores.

Introduction to Regulated Absorption

Ingestion of PSMs presents a physiological challenge for herbivores. PSMs that are ingested and absorbed exert a variety of deleterious effects on tissues and organs (Polya, 2003). Furthermore, the toxicity of PSMs is typically concentration-dependent and is therefore correlated with both the quantity of PSM ingested and the quantity of PSM that is absorbed and available throughout the body via the general circulation (Schumacher-Henrique et al., 2003; Orafidiya et al., 2004).

Because of the ubiquity of secondary metabolites in plants, herbivores cannot simply avoid them, but must employ mechanisms that minimize their levels in the circulation. Detoxification is currently regarded as the major physiological process that regulates the pharmacological distribution of PSMs in the body (Rosenthal and Berenbaum, 1992; Foley et al., 1999). In general, the process of detoxification biotransforms toxic PSMs into water-soluble metabolites that can be readily excreted. Although detoxification can lead to the formation of more toxic metabolites, the detoxification process typically results in a reduction in concentrations of toxic PSMs in the body. Moreover, several studies on insects have demonstrated that increased levels and activity of detoxification via enzymes are correlated with increased intake levels of certain PSMs in various herbivores. For example, the induction of cytochrome P-450 monooxygenases by PSMs, xanthotoxin and nicotine, is associated with high tolerance to these in the corn earworm (*Helicoverpa zea*) and tobacco hornworms (*Manduca sexta*), respectively (Snyder and Glendinning, 1996; Li et al., 2000; Sasabe et al., 2004). Although several studies have investigated detoxification enzymes in mammalian herbivores (Boyle et al., 1999, 2000a,b; Pass et al., 1999, 2001, 2002; Ngo et al., 2000; Lamb et al., 2001, 2004), few have directly linked higher PSM tolerance with higher detoxification enzyme activity in mammals (Miranda et al., 1991).

Although detoxification clearly plays a significant role in enhancing the excretion of PSMs and is predicted to facilitate PSM intake in herbivores, it is not the only mechanism that can regulate PSM concentrations in the body. For PSMs to gain access to tissues and organs, absorption across the gastrointestinal tract must first occur. Therefore, mechanisms in the gut that limit absorption provide the first line of defense against ingested PSMs. Detoxification in the intestine, whether via enzymes from microbes (Scheline, 1973; Jones and Megarrity, 1986; Hammond, 1995; Bhat et al., 1998) or the herbivore (Rosenthal and Berenbaum, 1992; Ilett et al., 1993; Watkins, 1997; Berenbaum, 1999; Von Richter et al., 2004), can regulate the absorption and subsequent distribution of ingested PSMs in herbivores. However, several studies demonstrate that many ingested PSMs that possess chemical properties conducive to absorption are neither detoxified nor absorbed in the gut (Ohmart and Larsson, 1989; Southwell et al., 1995; Schmidt et al., 2000; Cooper, 2001). For example, ingested terpenes, highly lipophilic PSMs, are excreted unchanged in the feces of two species of herbivorous mammals (*Neotoma* spp.; Sorensen and Dearing, 2003) and in frass of insects (Gómez et al., 1999; Müller and Hilker, 1999; Evans et al., 2000; Southwell et al., 2003). Physical barriers that limit the passive diffusion of PSMs across the gut, such as the peritrophic matrix and surfactants, have been the only mechanisms proposed to explain this phenomenon (Lehane, 1997; Barbehenn and Martin, 1998; Barbehenn, 2001). However, insights from biomedical and pharmaceutical research suggest that active transport of xenobiotics, including PSMs, out of enterocytes and into the gut lumen is also common and provides an efficient barrier against the absorption of lipophilic xenobiotics.

Mechanisms of Regulated Absorption

Despite the lack of attention from scientists who study plant–herbivore interactions, the biochemical mechanisms that actively regulate the absorption of ingested compounds are well known to medical scientists (Hunter and Hirst, 1997; Sharom,

1997; Watkins, 1997; Benet and Cummins, 2001; Doherty and Charman, 2002; Schinkel and Jonker, 2003). The molecules best known for their capacity to regulate the absorption of xenobiotics are collectively known as ATP-binding cassette (ABC) transporters. Permeability glycoprotein, or P-glycoprotein (P-gp), is encoded by the Multidrug Resistance (MDR) gene, and is one of over 200 ABC transporters that has been identified as playing a significant role in regulating bioavailability, or tissue distribution, of xenobiotics (Dietrich et al., 2003; Chan et al., 2004). Like other ABC transporters, P-gp is primarily expressed in the apical membrane of cells in barrier tissues, including the intestine, liver, kidney, testes, uterus, and blood-brain barrier. However, unlike other ABC transporters, P-gp is not substrate-specific and is capable of transporting a variety of structurally diverse compounds, including natural products (Sharom, 1997; Seelig and Landwojtowicz, 2000; Schinkel and Jonker, 2003). Although P-gp is a promiscuous transporter, most P-gp substrates are organic, relatively lipophilic, and contain polar or nonpolar domains (i.e., amphipathic, Sharom, 1997; Schinkel and Jonker, 2003).

P-gp is a major factor influencing the relationship between dose, blood concentration, and response of many orally administered drugs in humans (Van Zuylen et al., 2000; Ayrton and Morgan, 2001; Funakoshi et al., 2003). In general, individuals with higher quantities of P-gp exhibit lower blood concentrations and greater fecal excretion of certain orally administered drugs (Debenham et al., 1982; Van Zuylen et al., 2000). P-gp is also known to govern the bioavailability of many drugs resulting in lower pharmacological effect (Van Asperen et al., 1996; Jonker et al., 1999; Schinkel, 1999). P-gp reduces the bioavailability of ingested xenobiotics in three ways (Fig. 1). First, it can directly limit absorption by actively effluxing ingested xenobiotics out of cells against a concentration gradient via an ATP-dependent pump (Sharom, 1997; Dietrich et al., 2003). Second, it can indirectly




Fig. 1 Schematic representation of the functional role of P-glycoprotein (P-gp) and cytochrome P-450 3A (CYP3A) in regulating the absorption of ingested xenobiotics (X, i.e., drugs or plant secondary metabolites) in the gastrointestinal tract (GIT). P-gp and CYP3A can regulate the absorption of ingested xenobiotics (X) and detoxification metabolites (Xm) resulting in fecal excretion of these molecules via three scenarios. Ingested xenobiotics that are substrates of P-gp can be directly effluxed out of cells by P-gp (A). CYP3A metabolizes xenobiotics, which may result in absorption of the xenobiotic metabolite across the basolateral membrane (B). Finally, if the xenobiotic metabolite is a P-gp substrate, P-gp can efflux the metabolite out of cells (C)

reduce the bioavailability of ingested xenobiotics by regulating concentrations of intracellular xenobiotics to levels within the capacity of associated detoxification enzymes in cells, particularly cytochrome P-450 3A enzymes (Watkins, 1997; Ayrton and Morgan, 2001; Benet and Cummins, 2001). P-gp and CYP3A are colocalized in the villus tip of enterocytes, share many of the same substrates, and demonstrate broad overlap in substrate specificities (Kim et al., 1999; Katoh et al., 2001; Zhang and Benet, 2001). These attributes suggest that P-gp and CYP3A act in concert as a barrier to drug absorption. Finally, P-gp can efflux detoxification metabolites out of cells, thereby reducing the absorption of potentially toxic metabolites in addition to ingested parent xenobiotics (Katoh et al., 2001). In terms of drug therapy, mechanisms that limit absorption, enhance excretion, and minimize delivery of drugs to target tissues are medically problematic. For example, P-gp present in the transmembrane of cancer cells prevents the absorption of chemotherapeutic drugs (Lin and Yamazaki, 2003). Furthermore, because P-gp is a promiscuous transporter, it effluxes a wide range of anticancer drugs out of cells, resulting in the multidrug resistance phenomenon in cancer patients (Bellamy, 1996; Sparreboom et al., 2003). However, the same mechanisms that limit drug distribution in humans may also minimize the distribution of deleterious PSMs and prove beneficial to herbivores. In the following sections, we provide evidence that P-gp, or similar active transporters, may be employed by herbivores to enhance excretion and limit the bioavailability of ingested PSMs.

Evidence for Efflux Transporters in Herbivores

The first line of evidence that active transporters such as P-gp may be present in herbivores is the ubiquity and conservation of P-gp-like molecules among organisms. P-gp has been identified within mammals (humans, mice, rats, primates, dogs) and among distantly related taxa, such as bacteria, nematodes, insects, fish, birds, and plants (Dudler and Hertig, 1992; Lanning et al., 1996a; Davies et al., 1997; Barnes, 2001; Doi et al., 2001; Saier and Paulsen, 2001; Buss et al., 2002; Smith and Prichard, 2002; Mikkaichi et al., 2004). Furthermore, the sequence of P-gp is highly conserved across taxa (UCS Genome Bioinformatics website, <http://genome.ucsc.edu>). For example, the P-gp homologue in the plant, *Arabidopsis thaliana*, shares seven of nine introns with mammalian P-gp to within a few nucleotides (Dudler and Hertig, 1992). The shared sequence, organizational structure, and function of P-gp among distantly related organisms indicate that insect and mammalian herbivores will likely have P-gp homologues. Although empirical studies on P-gp in herbivores are minimal, the few species that have been investigated do possess P-gp or P-gp-like mechanisms. For example, P-gp-like transporters have been identified in the tobacco budworm, and appear to actively transport xenobiotics out of cells in these insects (Lanning et al., 1996a; Gaertner et al., 1998). Studies on herbivorous woodrats also demonstrate that several species of mammalian herbivores possess P-gp (Green et al., 2004).

A second piece of corroborating evidence is that a large number of PSMs that are potentially consumed by herbivores are substrates for P-gp (Patel et al., 2004; Zhou et al., 2004). Alkaloids, such as vinblastine from *Vinca rosea* (periwinkle, Burns, 1972; Sharom, 1997) and more recently, piperine from black (*Piper nigrum* Linn) and long pepper (*P. longum* Linn), are P-gp substrates (Bhardwaj et al., 2002).

Others include diterpene from *Euphorbia* (spurges, Hohmann et al., 2002; Appendino et al., 2003), phenolic glycosides from foxglove (*Digitalis lanata*, Kim et al., 1999; Katoh et al., 2001; Funakoshi et al., 2003), curcumin from *Curcumin longa* (Limtrakul et al., 2004), ginsenosides from ginseng (Choi et al., 2003; Kim et al., 2003), catachins from green tea (*Camellia sinensis*, Wang et al., 2002), bergamotin from grapefruits (Ohnishi et al., 2000; Wang et al., 2001), and hypericin from Saint John's wort (*Hypericum perforatum*, Wang et al., 2004).

The third line of evidence that active transporters such as P-gp are present in intestines of herbivores is the excretion of unmetabolized PSMs in the feces. A single study demonstrated that mammals (*Neotoma* spp.) excrete large quantities of ingested PSMs unmetabolized in the feces (Sorensen et al., 2004). Other examples of fecal excretion of unchanged compounds are found in herbivorous insects. For example, a large proportion of ingested nicotine is excreted unmetabolized in the feces of several insects specializing on tobacco (Self et al. 1964a,b; Snyder et al., 1994). Several other insect herbivores excrete terpenes in the feces that are identical in chemical structure and proportion to those found in the plants they consume (Gómez et al., 1999; Evans et al., 2000).

We propose that active transport of PSMs out of enterocytes is a plausible explanation for the fecal excretion of many unmetabolized PSMs in herbivores. Although passive barriers, such as peritrophic membranes (PMs), may be important in limiting the absorption of large complex PSMs, such as tannins (Barbehenn, 2001), these barriers would not be effective against small lipophilic compounds. Many of the PSMs excreted unmetabolized in the feces of herbivores, such as terpenes, are small molecules, highly lipophilic and, therefore, not likely to be passively filtered by PMs. Moreover, PMs cannot explain the excretion of terpenes unchanged in the feces of mammalian herbivores (Sorensen et al., 2004) because mammals do not possess PMs (Lehane, 1997). Instead, the excretion of many unmetabolized PSMs in the feces of herbivores is likely attributable to an active transporter such as P-gp. In support, a nicotine pump similar to P-gp has been identified in both malpighian tubules and in the blood-brain barrier of the tobacco hornworm (Murray et al., 1994; Gaertner et al., 1998). Finally, the strong correlation between the lipid solubility of a compound and its ability to interact with P-gp suggests that lipophilic PSMs are substrates for transporter proteins (Zamora et al., 1988; Schinkel and Jonker, 2003).

Although the excretion of unmetabolized lipophilic PSMs in the feces suggests that P-gp-like mechanisms are present in herbivores, the majority of studies fail to detect large quantities of unmetabolized PSMs in the feces of herbivores (Foley et al., 1987; Boyle et al., 1999, 2000a,b). We argue that these results do not necessarily indicate that most herbivores do not possess or utilize transporter proteins to minimize PSM bioavailability. Instead, the lack of unmetabolized PSMs in the feces may be attributable to the complex interactions between transporter proteins, detoxification enzymes, and microbes in the intestine prior to absorption. PSMs that are not absorbed may be detoxified or degraded by enzymes or microbes in the hindgut prior to excretion. For example, detoxification enzymes, particularly cytochrome P-450 3A, are locally associated and share substrate affinity with P-gp (Watkins, 1997; Kim et al., 1999; Zhang and Benet, 2001; Doherty and Charman, 2002). In addition, intestinal microbes from a variety of herbivores are known to metabolize and degrade PSMs (Carlson and Breeze, 1984; Jones and Megarrity, 1986; Hammond, 1995). Specifically, many microbes metabolize and degrade

lipophilic terpenes (Harder and Probian, 1995; Misra et al., 1996), which are likely P-gp substrates. Therefore, it is possible for P-gp to regulate the absorption of ingested PSMs in herbivores, but unmetabolized PSMs in the feces would not be present because of detoxification and modification of PSMs by enzymes and microbes prior to excretion. Alternatively, the rate of absorption of highly lipophilic compounds may exceed the rate of efflux by P-gp-like mechanisms resulting in absorption of PSMs that are actually P-gp substrates.

New Directions

It is essential to identify ways to isolate the contribution of active transport proteins in regulating PSM absorption in herbivores to better understand foraging constraints and disparate foraging strategies among herbivorous species. In this work, we suggest several areas of future research for chemical ecologists to better understand the interactions between PSMs and herbivores. Because of the preponderance of research on the function of P-gp, the following hypotheses will focus on assays and predictions for P-gp, but could be potentially applied to any efflux transporter protein.

The first needed area of research is to test the overall presence and level of transporter proteins in herbivores by using molecular techniques. The presence and quantity of particular proteins such as P-gp can be determined by using a combination of Western blots and quantitative polymerase chain reactions (qPCR). Western blots with monoclonal antibodies have been used to quantify P-gp in a variety of organisms, including herbivorous woodrats (Scheffer et al., 2000; Barnes, 2001; Doi et al., 2001; Green et al., 2004). Application of this method is accessible to a number of species because of the high conservation of monoclonal antibodies across species. Although this approach has been successfully applied to several species of animals, a potential limitation is the possible cross-reaction with proteins other than P-gp (Van Den Elsen et al., 1999) and the semiquantitative nature of the assay. Quantification of P-gp mRNA provides a more robust approach to identify and quantify P-gp in specific species of herbivores. Because sequences have not been determined for many wild species, species-specific sequences must be generated. In general, this process involves designing primary PCR primers from homologous sequences of nearest relatives, sequencing and verifying PCR products against known homologues to confirm identity, and then designing species-specific probes for qPCR. This approach was successfully used for plants (Dudler and Hertig, 1992; Yazaki et al., 2001; Sasaki et al., 2002), and will likely provide similar success in other species. An example of sequence alignment for a P-gp-like gene in plants and mammals is found in Dudler and Hertig (1992) and can provide an initial starting place for designing primers. In addition, homologous sequences can be designed based on P-gp (often referred to as MDR) gene alignments generated from the UCS Genome Bioinformatics website (<http://genome.ucsc.edu>). Quantitative PCR is beneficial in that it provides P-gp specificity and an opportunity to identify particular changes in P-gp sequence with respect to species, foraging strategies, and the type of PSM consumed. Quantification of P-gp-like transporters should not be restricted to segments of the gastrointestinal tract and should include studies in “barrier” tissues, such as the Malpighian tubules, liver, kidney, brain, testes, and uterus.

Given the likely applicability of these assays for P-gp quantification in herbivores, several hypotheses can be tested. First, these assays can be used to indirectly test the hypothesis that specific PSMs ingested by herbivores are substrates for P-gp. In general, ingestion of P-gp substrates yields an increase in P-gp concentrations (Benet and Cummins, 2001; Fromm, 2003, 2004; Lin and Yamazaki, 2003; Zhou et al., 2004). Determining whether a PSM is a P-gp substrate can be further verified with *in vitro* assays that use P-gp expressing cell lines (Varma et al., 2003; Moaddel et al., 2004; Wang et al., 2004) and/or *in vivo* studies that use P-gp knockout mice (Schinkel et al., 1997).

Second, assays can be employed to test the hypothesis that specialist herbivores rely on regulated absorption to a greater extent than generalist herbivores. Several studies that investigate the excretion of unchanged metabolites indirectly support this hypothesis. For example, the juniper specialist (*N. stephensi*) excreted a larger proportion (28%) of orally ingested alpha-pinene, the predominant PSM in juniper, in the feces than a closely related juniper generalists (*N. albigula*; 15%, (Sorensen et al., 2004). Similarly, specialist koalas excreted 15% of ingested eucalyptus oils, primarily composed of terpenes, in the feces (Eberhard et al., 1975) compared to 3% in a generalist counterpart, the brushtail possums (Foley et al., 1987). These results emphasize the need to quantify and compare P-gp activity, PSM intake, and fecal excretion of PSMs in additional specialist and generalist herbivores. Analytical techniques for quantification of unchanged PSMs include gas chromatography and high-pressure liquid chromatography; however, specific analysis is dependent on the chemistry of the particular PSM.

Quantitative assays can also be used to investigate the hypothesis that mechanisms regulating PSM absorption are positively correlated with expression of P-450 enzymes, specifically CYP3A, in the intestine. This prediction is based on the observation of large substrate overlap in CYP3A and P-gp within some species (Kim et al., 1999; Benet and Cummins, 2001; Katoh et al., 2001; Zhang and Benet, 2001). Furthermore, these molecules are typically located near one another and are thought to function in tandem. Chemical and physiological ecologists could, therefore, simultaneously compare P-gp and CYP3A levels along with the excretion of unmetabolized and metabolized PSMs in the feces when determining the role of P-gp in herbivory.

Finally, the ability to sequence, quantify, and test substrate affinity for P-gp makes it possible to investigate how generalists cope pharmacologically with a chemically diverse diet. Generalists are typically exposed to a wide and unpredictable array of PSMs because they consume taxonomically, and therefore, chemically diverse plant species, whereas specialists typically consume higher concentrations of a less diverse spectrum of PSMs because they consume plants within a narrow taxon range. It is theorized that generalists possess greater structural and functional flexibility in counterdefense mechanisms against PSMs (Gatehouse, 2002; Li et al., 2004). Greater polymorphisms in P-450 detoxification enzymes have been identified in a population of generalist insect herbivores (*H. zea*), and these are associated with wider substrate breadth compared to a population of specialists (*Papilio polyxenes*; Li et al., 2004). We predict that investigation on P-gp sequence and substrate affinity will reveal that generalist populations have greater P-gp polymorphisms that broaden substrate affinity compared to specialists. These tests will further describe the molecular and genetic disparity in counterdefenses between specialist and generalist herbivores.

Transporter proteins may not only be involved in the excretion of PSMs in feces, but may also explain the mechanisms for their sequestration in insects. Many herbivores “shuttle” ingested PSMs against a concentration gradient and sequester them unmetabolized in diverticular pouches, defensive glands, or hemolymph (Eisner et al., 1974; Müller and Hilker, 1999; Schmidt et al., 2000; Nishida, 2002; Pasteels and Hartmann, 2004). To date, no specific transporter has been implicated for the movement of these PSMs. However, there is recent evidence that selective transport systems are responsible for sequestration of certain metabolites in tissues of insects (Pasteels and Hartmann, 2004). In addition, transporter proteins have been proposed as a mechanism employed by plants to sequester PSMs in vacuoles, thereby protecting plant cells from the consequences of PSM exposure (Debeaujon et al., 2001; Sakai et al., 2002).

P-gp and Secondary Compound Diversity

P-gp transporters and the secondary compounds that interfere with them may be key factors that contribute in part to the bewildering diversity of chemical defenses in plants. The astounding diversity of secondary compounds in many species of plants is thought to be the result of a biochemical “arms race,” or reciprocal evolution between plants and herbivores (Berenbaum et al., 1991; Fritz and Simms, 1992; Berenbaum, 1995, 1999; Castellanos and Espinosa-Garcia, 1997). The presence and abundance of P-gp transporters in their guts could represent an evolutionary counterresponse on the part of herbivores that reduces the physiological effect of secondary compounds by decreasing the quantity of “potent” PSM absorbed into the tissues. As a consequence of P-gp transporters, plants may have evolved secondary compounds that directly interfere with P-gp transporters that thereby enhance toxicity through increased absorption of potent secondary compounds. We refer to the P-gp inhibitors as “potency enhancers” because they act to increase the absorption of compounds that are biologically potent, or bioactive. Examples of PSMs that reduce the effectiveness of P-gp and enhance the absorption of potent compounds include furanocoumarins from grapefruits (Ohnishi et al., 2000; Wang et al., 2001; Honda et al., 2004), quercetin in oaks and birches (Shapiro and Ling, 1997; Conseil et al., 1998), and diterpenoids in spurge (Hohmann et al., 2002; Appendino et al., 2003). Although no work exists on the synergism between “potency enhancers” that inhibit P-gp and secondary compound diversity, some plant species with P-gp inhibitors also produce potent lipophilic compounds (e.g., terpenes in grapefruit) that could be P-gp substrates. Obviously, more research is necessary to critically evaluate these speculations.

In contrast, secondary compounds have been described that activate P-gp transporters, thereby reducing absorption of other compounds (Dürr et al., 2000; Perloff et al., 2001). For example, in *in vitro* experiments with cell cultures, the administration of hypericin extracted from St. John’s wort elevates P-gp expression by 700% and significantly decreases the absorption of P-gp substrates (Perloff et al., 2001). The object of that study, as well as the others, was to identify compounds that interfere with the absorption of pharmaceuticals. Thus, the amount of activators applied may be far greater than the natural concentration of these compounds in plant tissues. Whether P-gp-activating compounds have synergistic effects on cooccurring secondary compounds at natural concentrations in plants when consumed by herbivores has not been examined. In theory, P-gp activators should

reduce the bioavailability of other coingested secondary compounds that are P-gp substrates. The adaptive significance to the plant of P-gp-activating compounds is not obvious. However, if P-gp activating compounds are produced at active concentrations in plants, the possibility exists that generalist herbivores take advantage of such compounds to reduce the absorption of secondary compounds from other plants in their diet. Thus, foraging behavior of herbivores may ultimately depend on the presence or absence of PSMs that are P-gp substrates, as well as on the presence of P-gp inhibitors and activators.

Broader Implications

Exploring how PSMs interact with transporter proteins and the relative role of these interactions in PSM tolerance in herbivores will not only contribute to understanding plant–herbivore interactions, but will likely have farther reaching applications. For example, the identification of PSMs that inhibit transporter proteins may contribute to a more efficient drug therapy. For example, a major complication in cancer therapy is due to multidrug resistance in cancer cells afforded by P-gp (Bellamy, 1996; Ambudkar et al., 2003). There is a pressing need to identify natural products and synthesize drugs that directly inhibit P-gp without concomitant toxicity to normal cells. Integration of knowledge from chemical ecologists who can predict which plants are most likely to possess P-gp inhibitors, and knowledge from pharmacologists who can predict which molecules are most likely to inhibit P-gp could facilitate the identification of compounds that enhance chemotherapy. Specifically, ecological knowledge of plant defenses and those acted on by active transporters may advance drug discovery. For example, assuming that P-gp is important in regulating the absorption of potent PSMs and that P-gp may be more important in specialist herbivores than generalists (Green et al., 2004; Sorensen et al., 2004), we can predict that leaves fed on by specialists contain compounds that are P-gp substrates, but are also likely to be potent drugs for humans. Moreover, we propose that individual plants or leaves within a host plant that are avoided by specialists may contain potency enhancers, compounds that inhibit the function of P-gp. We suggest that by applying the relationship between foraging strategies of herbivores and regulated absorption, a model can be used to efficiently target plants that contain potent compounds or potency enhancers. Further research into this area of plant–herbivore interactions could reveal the bioprospecting potential of herbivores.

Identifying active transporters in herbivores and PSMs that block the function of transporters could also be important in controlling both plant and animal pest species. Several pesticides, herbicides, anthelmintics, acaricides, and amebicides are P-gp substrates (Abu-Qare et al., 2003; Schinkel and Jonker, 2003). In addition, the absorption of many of these pesticides is limited by P-gp-like activity in insects (Lanning et al. 1996a,b; Buss et al., 2002; Srinivas et al., 2004) and plants (Windsor et al., 2003). The prevalence of P-gp may, therefore, help explain insect and plant resistance to pesticides and herbicides. Manipulation of transporters that regulate toxin absorption could be applied to development of more effective pest control agents. For example, pesticides that are P-gp substrates might be more effective if they were administered along with known P-gp inhibitors. This practice could result

in higher quantities of pesticides absorbed per unit exposure, thereby reducing the amount of pesticide used and/or increasing the susceptibility of insects to pesticides.

Acknowledgments We thank W. J. Foley, S. McLean, K. Smith, and two anonymous reviewers for comments on the manuscript. Research was supported by NSF International Research Fellowship INT-0301898 to J. S. Sorensen and NPS IBN-0236402 to M.D. Dearing.

References

- ABU-QARE, A. W., EMLASRY, E., and ABOU-DONIA, M. B. 2003. A role for P-glycoprotein in environmental toxicology. *J. Toxicol. Environ. Health B Crit. Rev.* 6:279–288.
- AMBUDKAR, S. V., KIMCHI-SARFATY, C., SAUNA, Z. E., and GOTTESMAN, M. M. 2003. P-glycoprotein: from genomics to mechanism. *Oncogene* 22:7468–7485.
- APPENDINO, G., PORTA, C., CONSEIL, G., STERNER, O., MERCALLI, E., DUMONTET, C., and DI PEITRO, A. 2003. A new P-glycoprotein inhibitor from the caper spurge (*Euphorbia lathyris*). *J. Nat. Prod.* 66:140–142.
- AYRTON, A. and MORGAN, P. 2001. Role of transport proteins in drug absorption, distribution and excretion. *Xenobiotica* 31:469–497.
- BARBEHENN, R. 2001. Roles of peritrophic membranes in protecting herbivorous insects from ingested plant allelochemicals. *Arch. Insect Biochem. Physiol.* 47:86–99.
- BARBEHENN, R. V. and MARTIN, M. M. 1998. Formation of insoluble and colloiddally dispersed tannic acid complexes in the midgut fluid of *Manduca sexta* (Lepidoptera: Sphingidae): an explanation for the failure of tannic acid to cross the peritrophic envelopes of lepidopteran larvae. *Arch. Insect Biochem. Physiol.* 39:109–117.
- BARNES, D. M. 2001. Expression of P-glycoprotein in the chicken. *Comp. Biochem. Physiol. A* 130:301–310.
- BELLAMY, W. T. 1996. P-glycoproteins and multidrug resistance. *Annu. Rev. Pharmacol. Toxicol.* 36:161–183.
- BENET, L. and CUMMINS, C. 2001. The drug efflux–metabolism alliance: biochemical aspects. *Adv. Drug Deliv. Rev.* 50:S3–S11.
- BERENBAUM, M. R. 1995. Chemical defense: Theory and practice. *Proc. Nat. Acad. Sci. USA* 92:2–8.
- BERENBAUM, M. R. 1999. Animal–plant warfare: molecular basis for cytochrome P450-mediated natural adaptation, pp. 553–571, in A. Puga and K. Wallace (eds.). *Molecular Biology of the Toxic Response*. Taylor and Francis, Philadelphia.
- BERENBAUM, M. R., NITAO, J. K., and ZANGERL, A. R. 1991. Adaptive significance of furanocoumarin diversity in *Pastinaca sativa* (Apiaceae). *J. Chem. Ecol.* 17:207–215.
- BHARDWAJ, R., GLAESER, H., BECQUEMONT, L., KLOTZ, U., GUPTA, S., and FROMM, M. 2002. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. *J. Pharmacol. Exp. Ther.* 302:645–650.
- BHAT, T. K., SINGH, B., and SHARMA, O. P. 1998. Microbial degradation of tannins—a current perspective. *Biodegradation* 9:343–357.
- BOYLE, R., McLEAN, S., FOLEY, W. J., and DAVIES, N. W. 1999. Comparative metabolism of dietary terpene, *p*-cymene, in generalist and specialist folivorous marsupials. *J. Chem. Ecol.* 25:2109–2127.
- BOYLE, R., McLEAN, S., and DAVIES, N. W. 2000a. Biotransformation of 1,8-cineole in the brushtail possum (*Trichosurus vulpecula*). *Xenobiotica* 30:915–932.
- BOYLE, R., McLEAN, S., FOLEY, W. J., MOORE, B. D., DAVIES, N. W., and BRANDON, S. 2000b. Fate of the dietary terpene, *p*-cymene, in the male koala. *J. Chem. Ecol.* 26:1095–1111.
- BURNS, J. H. (ed.) 1972. *Analytical Profiles of Drug Substances*. Academic Press, New York.
- BUSS, D. S., McCAFFERY, A. R., and CALLAGHAN, A. 2002. Evidence for p-glycoprotein modification of insecticide toxicity in mosquitoes of the *Culex pipiens* complex. *Med. Vet. Entomol.* 16:218–222.
- CARLSON, J. R. and BREEZE, R. G. 1984. Ruminal metabolism of plant toxins with emphasis on indolic compounds. *J. Anim. Sci.* 58:1040–1049.
- CASTELLANOS, I. and ESPINOSA-GARCIA, F. J. 1997. Plant secondary metabolite diversity as a resistance trait against insects: a test with *Sitophilus granarius* (Coleoptera: Curculionidae) and seed secondary metabolites. *Biochem. Syst. Ecol.* 25:591–602.

- CHAN, L. M. S., LOWES, S., and HIRST, B. H. 2004. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. *Eur. J. Pharm. Sci.* 21:25–51.
- CHEEKE, P. R. 1998. *Natural Toxicants in Feeds and Poisonous Plants*, 2nd edn. Interstate Publishers, Danville, IL.
- CHOI, C., KANG, G., and MIN, Y. 2003. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. *Planta Med.* 69:235–240.
- CONSEIL, G., BAUBICHON-CORTAY, H., DAYAN, G., JAULT, J., BARRON, D., and DI PEITRO, A. 1998. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. *Proc. Natl. Acad. Sci. USA* 95:9831–9836.
- COOPER, P. D. 2001. What physiological processes permit insects to eat *Eucalyptus* leaves? *Austral. Ecol.* 26:556–562.
- DAVIES, T. G., THEODOULOU, F. L., HALLAHAN, D. L., and FORDE, B. G. 1997. Cloning and characterisation of a novel P-glycoprotein homologue from barley. *Gene* 199:195–202.
- DEBEAUXON, I., PEETERS, A. J. M., LÉON-KLOOSTERZIEL, K. M., and KOORNNEEF, M. 2001. The TRANSPARENT TESTA12 gene of *Arabidopsis* encodes a multidrug secondary transporter-like protein required for flavonoid sequestration in vacuoles of the seed coat endothelium. *Plant Cell* 13:853–871.
- DEBENHAM, P., KARTNER, N., SIMINOVITCH, L., RIORDAN, J., and LING, V. 1982. DNA mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. *Mol. Cell. Biol.* 2:881–889.
- DIETRICH, C. G., GEIER, A., and OUDE ELFERINK, R. P. J. 2003. ABC of oral bioavailability: transporters as gatekeepers in the gut. *Gut* 52:1788–1795.
- DOHERTY, M. M. and CHARMAN, W. N. 2002. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism. *Clin. Pharmacokinet.* 41:235–253.
- DOI, A. M., HOLMES, E., and KLEINOW, K. M. 2001. P-glycoprotein in the catfish intestine: inducibility by xenobiotics and functional properties. *Aquat. Toxicol.* 55:157–170.
- DUDLER, R. and HERTIG, C. 1992. Structure of an *mdr*-like gene from *Arabidopsis thaliana*. *J. Biol. Chem.* 267:5882–5888.
- DÜRR, D., STIEGER, B., KULLAK-UBLICK, G. A., RENTSCH, K. M., STEINERT, H. C., MEIER, P. J., and FATTINGER, K. 2000. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. *Clin. Pharmacol. Ther.* 68:598–604.
- EBERHARD, I. H., McNAMARA, J., PEARSE, R. J., and SOUTHWELL, I. A. 1975. Ingestion and excretion of *Eucalyptus punctata* D.C. and its essential oil by the koala *Phascolarctos cinereus*. *Aust. J. Zool.* 23:169–179.
- EISNER, T., JOHNESSEE, J. S., CARREL, J., HENDRY, L. B., and MEINWALD, J. 1974. Defensive use by an insect of a plant resin. *Science* 184:966–999.
- EVANS, P. H., BECERRA, J. X., VENABLE, D. L., and BOWERS, W. S. 2000. Chemical analysis of squirt-gun defense in *Bursera* and counterdefenses by Chrysomelid beetles. *J. Chem. Ecol.* 26:745–754.
- FOLEY, W. J., LASSAK, E. V., and BROPHY, J. B. 1987. Digestion and absorption of *Eucalyptus* essential oils in greater glider (*Petauroides volans*) and brushtail possums (*Trichosurus vulpecula*). *J. Chem. Ecol.* 13:2115–2130.
- FOLEY, J. W., IASON, G. R., and McARTHUR, C. 1999. Role of plant secondary metabolites in the nutritional ecology of mammalian herbivores: how far have we come in 25 years?, pp. 130–209, in H. G. Jung, G. C. Fahey (eds.). *Nutritional Ecology of Herbivores*. American Society of Animal Science, Savoy, IL.
- FREELAND, W. J. AND JANZEN, D. H. 1974. Strategies in herbivory by mammals: the role of plant secondary compounds. *Am. Nat.* 108:269–289.
- FRITZ, R. and SIMMS, E. 1992. *Plant Resistance to Herbivores and Pathogens: Ecology, Evolution, and Genetics*. University of Chicago Press, Chicago.
- FROMM, M. F. 2003. Importance of P-glycoprotein for drug disposition in humans. *Eur. J. Clin. Invest.* 33:6–9.
- FROMM, M. 2004. Importance of P-glycoprotein at blood–tissue barriers. *Trends Pharmacol. Sci.* 25:423–429.
- FUNAKOSHI, S., MURAKAMI, T., YUMOTO, R., KIRIBAYASHI, Y., and TAKANO, M. 2003. Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and β -methyl digoxin in rats. *J. Pharm. Sci.* 92:1455–1463.
- GAERTNER, L. S., MURRAY, C. L., and MORRIS, C. E. 1998. Transepithelial transport of nicotine and vinblastine in isolated malpighian tubules of the tobacco hornworm (*Manduca sexta*) suggests a P-glycoprotein-like mechanism. *J. Exp. Biol.* 201:2637–2645.

- GATEHOUSE, J. A. 2002. Plant resistance towards insect herbivores: A dynamic interaction. *New Phytol.* 156:145–169.
- GÓMEZ, N. E., WITTE, L., and HARTMANN, T. 1999. Chemical defense in larval tortoise beetles: Essential oil composition of fecal shields of *Eurypedus nigrosignata* and foliage of its host plant, *Cordia curassavica*. *J. Chem. Ecol.* 25:1007–1027.
- GREEN, A. K., HALEY, S., DEARING, M. D., BARNES, D. M., and KARASOV, W. H. 2004. Intestinal capacity of P-glycoprotein is higher in the juniper specialist, *Neotoma stephensi*, than the sympatric generalist, *Neotoma albigula*. *Comp. Biochem. Physiol. A* 139:325–333.
- HAMMOND, A. 1995. *Leucaena* toxicosis and its control in ruminants. *J. Anim. Sci.* 73:1487–1492.
- HARDER, J. and PROBIAN, C. 1995. Microbial degradation of monoterpenes in the absence of molecular oxygen. *Appl. Environ. Microbiol.* 61:3804–3808.
- HOHMANN, J., MOLNAR, J., REDEI, D., EVANICS, F., FORGO, P., KALMAN, A., ARGAY, G., and SZABO, P. 2002. Discovery and biological evaluation of a new family of potent modulators of multidrug resistance: reversal of multidrug resistance of mouse lymphoma cells by new natural jatrophone diterpenoids isolated from *Euphorbia* species. *J. Med. Chem.* 45:2425–2431.
- HONDA, Y., USHIGOME, F., KOYABU, N., MOROMOTO, S., SHOYAMA, Y., UCHIUMI, T., KUWANO, M., and OHTANI, H. 2004. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. *Br. J. Pharmacol.* 143:856–864.
- HUNTER, J. and HIRST, B. 1997. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. *Adv. Drug Deliv. Rev.* 25:129–157.
- ILETT, K., TEE, L., REEVES, P., and MINCHIN, R. 1993. Metabolism of drugs and other xenobiotics in the gut lumen and wall. *Pharmacol. Ther.* 46:67–93.
- JONES, R. and MEGARRITY, R. 1986. Successful transfer of dihydroxypyridine-degrading bacteria from Hawaiian (USA) goats to Australian ruminants to overcome the toxicity of *Leucaena*. *Aust. Vet. J.* 63:259–262.
- JONKER, J. W., WAGENAAR, E., VAN DEEMTER, L., GOTTSCHLICH, R., BENDER, H. M., DASENBROCK, J., and SCHINKEL, A. H. 1999. Role of blood–brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. *Br. J. Pharmacol.* 127:43–50.
- KARBAN, R. and AGRAWAL, A. A. 2002. Herbivore offense. *Annu. Rev. Ecol. Syst.* 33:641–664.
- KATOH, M., NAKAJIMA, M., and YOKOI, T. 2001. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. *Eur. J. Pharm. Sci.* 12:505–513.
- KIM, R. B., WANDEL, C., LEAKE, B., CVETKOVIC, M., FROMM, M. F., DEMPSEY, P. J., RODEN, M. M., BELAS, F., CHAUDHARY, A. K., RODEN, D. M., WOOD, A. J., and WILKINSON, G. R. 1999. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. *Pharm. Res.* 16:408–414.
- KIM, S. W., KWON, H. Y., CHI, D. W., SHIM, J. H., PARK, J. D., LEE Y. H., PYO, S., and DK, R. 2003. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). *Biochem. Pharmacol.* 65:75–82.
- LAMB, J. G., SORENSEN, J. S., and DEARING, M. D. 2001. Comparison of detoxification enzymes mRNAs in woodrats (*Neotoma lepida*) and laboratory rats. *J. Chem. Ecol.* 27:845–857.
- LAMB, J. G., CHATERJIE, P., MARICK, P., SORENSEN, J. S., HALEY, S., and DEARING, M. D. 2004. Liver biotransforming enzymes in woodrats *Neotoma stephensi* woodrats. *Comp. Biochem. Physiol. C* 138:139–148.
- LANNING, C. L., AYAD, H. M., and ABOU-DONIA, M. B. 1996a. P-glycoprotein involvement in cuticular penetrations of [¹⁴C]theidicarb in resistant tobacco budworms. *Toxicol. Lett.* 85:127–133.
- LANNING, C. L., FINE, R. L., CORCORAN, J. J., AYAD, H. M., ROSE, R. L., and ABOU-DONIA, M. B. 1996b. Tobacco budworm P-glycoprotein: Biochemical characterization and its involvement in pesticide resistance. *Biochim. Biophys. Acta.* 1291:155–162.
- LEHANE, M. 1997. Peritrophic matrix structure and function. *Annu. Rev. Entomol.* 42:525–550.
- LI, X., ZANGERL, A., SCHULER, M., and BERENBAUM, M. 2000. Cross-resistance to alpha-cypermethrin after xanthotoxin ingestion in *Helicoverpa zea* (Lepidoptera: Noctuidae). *J. Econ. Entomol.* 93:18–25.
- LI, X., BAUDRY, J., BERENBAUM, M. R., and SCHULER, M. A. 2004. Structural and functional divergence of insect CYP6B proteins: from specialist to generalist cytochrome P450. *Proc. Natl. Acad. Sci. USA* 101:2939–2944.
- LIMTRAKUL, P., ANUCHAPREEDA, S., and BUDDHASUKH, D. 2004. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. *BMC Cancer* 4:13.
- LIN, J. H. and YAMAZAKI, M. 2003. Clinical relevance of P-glycoprotein in drug therapy. *Drug Metab. Rev.* 35:417–454.

- MIKKAICHI, T., SUZUKI, T., ONOGAWA, T., TANEMOTO, M., MIZUTAMARI, H., OKADA, M., CHAKI, T., MASUDA, S., TOKUI, T., ETO, N., ABE, M., SATOH, F., UNNO, M., HISHINUMA, T., INUI, K., ITO, S., GOTO, J., and ABE, T. 2004. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. *Proc. Natl. Acad. Sci. USA* 101:3569–3574.
- MIRANDA, C. L., CHUNG, W., REED, R. E., ZHOU, X., HENDERSON, M. C., WANG, J. L., WILLIAMS, D. E., and BUHLER, D. R. 1991. Flavin-containing monooxygenase: a major detoxifying enzyme for the pyrrolizidine alkaloid senecionine in guinea pig tissues. *Biochem. Biophys. Res. Commun.* 178:546–552.
- MISRA, G., PAVLOSTATHIS, S. G., PERDUE, E. M., and ARAUJO, R. 1996. Aerobic biodegradation of selected monoterpenes. *Appl. Microbiol. Biotechnol.* 45:831–838.
- MOADDEL, R., BULLOCK, P. L., and WAINER, I. W. 2004. Development and characterization of an open tubular column containing immobilized P-glycoprotein for rapid on-line screening for P-glycoprotein substrates. *J. Chromatogr. B* 799:255–263.
- MÜLLER, C. and HILKER, M. 1999. Unexpected reactions of a generalist predator towards defensive devices of cassidine larvae (Coleoptera, Chrysomelidae). *Oecologia* 118:166–172.
- MURRAY, C. L., QUAGLIA, M., ARNASON, J. T., and MORRIS, C. E. 1994. A putative nicotine pump at the metabolic blood–brain-barrier of the tobacco hornworm. *J. Neurobiol.* 25:23–34.
- NEAL, I. J. 1987. Metabolic costs of mixed-function oxidase induction in *Heliothis zea*. *Entomol. Exp. Appl.* 43:175–179.
- NGO, S., KONG, S., KIRLICH, A., MCKINNON, R., and STUPANS, I. 2000. Cytochrome P450 4A, peroxisomal enzymes and nicotinamide cofactors in koala liver. *Comp. Biochem. Physiol. C* 127:327–334.
- NISHIDA, R. 2002. Sequestration of defensive substances from plants by Lepidoptera. *Annu. Rev. Entomol.* 47:57–93.
- OHMART, C. P. and LARSSON, S. 1989. Evidence for absorption of eucalypt essential oils by *Paropsis atomaria* Oliveira (Coleoptera: Chrysomelidae). *J. Aust. Entomol. Soc.* 28.
- OHNISHI, A., MATSUO, H., YAMADA, S., TAKANAGA, H., MORIMOTO, S., SHOYAMA, Y., OHTANI, H., and SAWADA, Y. 2000. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. *Br. J. Pharmacol.* 130:1369–1377.
- ORAFIDIYA, L., AGBANI, E., IWALEWA, E., ADELUSOLA, K., and OYEDAPO, O. 2004. Studies on the acute and sub-chronic toxicity of the essential oil of *Ocimum gratissimum* L. leaf. *Phytomedicine* 11:71–76.
- PALO, R. and ROBBINS, C. T. 1991. Plant Defenses Against Mammalian Herbivory. CRC Press, Boca Raton.
- PASS, G. J., McLEAN, S., and STUPANS, I. 1999. Induction of xenobiotic metabolising enzymes in the common brushtail possum, *Trichosurus vulpecula*, by *Eucalyptus* terpenes. *Comp. Biochem. Physiol. C* 124:239–246.
- PASS, G. J., McLEAN, S., STUPANS, I., and DAVIES, N. 2001. Microsomal metabolism of the terpene 1,8-cineole in the common brushtail possum (*Trichosurus velpecula*), koala (*Phascolarctos cinereus*), rat and human. *Xenobiotica* 31:205–221.
- PASS, G. J., McLEAN, S., STUPANS, I., and DAVIES, N. 2002. Microsomal metabolism and enzyme kinetics of the terpene *p*-cymene in the common brushtail possum (*Trichosurus velpecula*), koala (*Phascolarctos cinereus*) and rat. *Xenobiotica* 32:383–397.
- PASTEELS, J. M. and HARTMANN, T. 2004. Sequestration of pyrrolizidine alkaloids in Oreina and Platyphora leaf-beetles: physiological, ecological and evolutionary aspects, pp. 677–691, in P. Jolivet, J. A. Santiago-Blay, and M. Schmitt (eds.). New Developments in the Biology of Chrysomelidae. SPB Academic Publishing, The Hague, The Netherlands.
- PATEL, J., BUDDHA, B., DEY, S., PAL, D., and MITRA, A. 2004. *In vitro* interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. *Am. J. Ther.* 11:262–277.
- PERLOFF, M. D., VON MOLTKE, L. L., STORMER, E., SHADER, R. I., and GREENBLATT, D. J. 2001. Saint John's wort: an *in vitro* analysis of P-glycoprotein induction due to extended exposure. *Br. J. Pharmacol.* 134:1601–1608.
- POLYA, G. 2003. Biochemical Targets of Plant Bioactive Compounds: A Pharmacological Reference Guide to Sites of Action and Biological Effects. CRC Press.
- ROSENTHAL, G. A. and BERENBAUM, M. R. 1992. Herbivores: Their Interaction with Secondary Plant Metabolites, 2nd edn. Academic Press, New York.
- SAIER, M. H. J. and PAULSEN, I. T. 2001. Phylogeny of multidrug transporters. *Cell Dev. Biol.* 12:205–213.

- SAKAI, K., SHITAN, N., SATO, F., UEDA, K., and YAZAKI, K. 2002. Characterization of berberine transport into *Coptis japonica* cells and the involvement of ABC protein. *J. Exp. Bot.* 53:1879–1886.
- SASABE, M., WEN, Z., BERENBAUM, M., and MA, S. 2004. Molecular analysis of CYP321A1, a novel cytochrome P450 involved in metabolism of plant allelochemicals (furanocoumarins) and insecticides (cypermethrin) in *Helicoverpa zea*. *Gene* 338:163–175.
- SASAKI, T., EZAKI, B., and MATSUMOTO, H. 2002. A gene encoding multidrug resistance (MDR)-like protein is induced by aluminum and inhibitors of calcium flux in wheat. *Plant Cell Physiol.* 43:177–185.
- SCHAEFFER, G. L., KOOL, M., HEIJN, M., DE HAAS, M., PIJNBORG, A. C. L. M., WIJNHOLDS, J., VAN HELVOORT, A., DE JONG, M. C., HOOLBERG, J. H., MOL, C. A. A. M., VAN DER LINDEN, M., DE VREE, J. M. L., VAN DER VALK, P., ELFERINK, R. P. J. O., BORST, P., and SCHEPER, R. J. 2000. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. *Cancer Res.* 60:5269–5277.
- SCHELINE, R. 1973. Metabolism of foreign compounds by gastrointestinal microorganisms. *Pharmacol. Rev.* 25:451–523.
- SCHINKEL, A. H. 1999. P-glycoprotein, a gatekeeper in the blood–brain barrier. *Adv. Drug Deliv. Rev.* 36:179–194.
- SCHINKEL, A. H. and JONKER, J. W. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. *Adv. Drug Deliv. Rev.* 55:3–29.
- SCHINKEL, A. H., MAYER, U., WAGENAAR, E., MOL, C. A. A. M., VAN DEEMTER, L., SMIT, J., ZIJLMANS, J. M., FIBBE, W. E., and BORST, P. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. *Proc. Natl. Acad. Sci. USA* 94:4028–4033.
- SCHMIDT, S., WALTER, G. H., and MOORE, C. J. 2000. Host plant adaptations in myrtaceous-feeding Pergid sawflies: essential oil and the morphology and behavior of *Pergagrapta* larvae (Hymenoptera, Symphyta, Pergidae). *Biol. J. Linn. Soc.* 70:15–26.
- SCHUMAHER-HENRIQUE, B., GORNIK, S., DAGLI, M., and SPINOSA, H. 2003. The clinical, biochemical, haematological and pathological effects of long-term administration of *Ipomoea carnea* to growing goats. *Vet. Res. Commun.* 27:311–319.
- SEELIG, A. and LANDWOJTOWICZ, E. 2000. Structure–activity relationship of P-glycoprotein substrates and modifiers. *Eur. J. Pharm. Sci.* 12:31–40.
- SELF, L. S., GUTHRIE, F. E., and HODGSON, E. 1964a. Adaptation of tobacco hornworms to the ingestion of nicotine. *J. Insect Physiol.* 10:907–914.
- SELF, L. S., GUTHRIE, F. E., and HODGSON, E. 1964b. Metabolism of nicotine by tobacco-feeding insects. *Nature* 204:300–301.
- SHAPIRO, A. B. and LING, V. 1997. Effect of quercetin on hoechst 33342 transport by purified and reconstituted P-glycoprotein. *Biochem. Pharmacol.* 53:587–596.
- SHAROM, F. 1997. The P-glycoprotein efflux pump: how does it transport drugs? *J. Membr. Biol.* 160:161–175.
- SMITH, J. M. and PRICHARD, R. K. 2002. Localization of P-glycoprotein mRNA in the tissues of *Haemonchus contortus* adult worms and its relative abundance in drug-selected and susceptible strains. *J. Parasitol.* 88:612–620.
- SNYDER, M. and GLENDINNING, J. 1996. Causal connection between detoxification enzyme activity and consumption of a toxic plant compound. *J. Comp. Physiol. A* 179:255–261.
- SNYDER, M. J., WALDING, K. J., and FEYEREISEN, R. 1994. Metabolic fate of the allelochemical nicotine in the tobacco hornworm *Manduca sexta*. *Insect Biochem. Mol. Biol.* 24:837–846.
- SORENSEN, J. S. and DEARING, M. D. 2003. Elimination of plant toxins: an explanation for dietary specialization in mammalian herbivores. *Oecologia* 134:88–94.
- SORENSEN, J. S., TURNBULL, C. A., and DEARING, M. D. 2004. A specialist herbivore (*Neotoma stephensi*) absorbs fewer plant toxins than a generalist (*Neotoma albigula*). *Physiol. Biochem. Zool.* 77:139–148.
- SORENSEN, J. S., MCCLISTER, J. D., and DEARING, M. D. 2005. Plant secondary metabolites compromise the energy budgets of specialist and generalist mammalian herbivores. *Ecology* 86:125–139.
- SOUTHWELL, I. A., MADDOX, C. D. A., and ZALUCKI, M. P. 1995. Metabolism of 1,8-cineole in tea tree (*Melaleuca alternifolia* and *M. linariifolia*) by pyrgo beetle (*Paropsisterna tigrina*). *J. Chem. Ecol.* 21:439–453.
- SOUTHWELL, I., RUSSELL, M., MADDOX, C., and WHEELER, G. 2003. Differential metabolism of 1,8-cineole in insects. *J. Chem. Ecol.* 29:83–94.

- SPARREBOOM, A., DANESI, R., ANDO, Y., CHAN, J., and FIGG, W. D. 2003. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. *Drug Resist. Updat.* 2:71–84.
- SRINIVAS, R., UDIKERI, S. S., JAYALAKSHMI, S. K., and SREERAMULU, K. 2004. Identification of factors responsible for insecticide resistance in *Helicoverpa armigera*. *Comp. Biochem. Physiol. C* 137:261–269.
- VAN ASPEREN, J., SCHINKEL, A. H., BEIJNEN, J. H., W.J., N., BORST, P., and VAN TELLINGEN, O. 1996. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. *J. Natl. Cancer Inst.* 88:994–999.
- VAN DEN ELSEN, J. M. H., KUNTZ, D. A., HOEDEMAEKER, F. J., and ROSE, D. R. 1999. Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein. *Proc. Natl. Acad. Sci. USA* 96:13679–13684.
- VAN ZUYLEN, L., VERWEIJ, J., NOOTER, K., BROUWER, E., STOTER, G., and SPARREBOOM, A. 2000. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. *Clin. Cancer Res.* 6:2598–2603.
- VARMA, M. V. S., ASHOKRAJ, Y., DEY, C. S., and PANCHAGNULA, R. 2003. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. *Pharm. Res.* 48:347–359.
- VON RICHTER, O., BURK, O., FROMM, M., THON, K., EICHELBAUM, M., and KIVISTO, K. 2004. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. *Clin. Pharmacol. Ther.* 75:172–183.
- WANG, E. J., CASCIANO, C. N., CLEMENT, R. P., and JOHNSON, W. W. 2001. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. *Pharm. Res.* 18:432–438.
- WANG, E. J., BARECKI-ROACH, M., and JOHNSON, W. W. 2002. Elevation of P-glycoprotein function by a catechin in green tea. *Biochem. Biophys. Res. Commun.* 297:412–418.
- WANG, E. J., BARECKI-ROACH, M., and JOHNSON, W. W. 2004. Quantitative characterization of direct P-glycoprotein inhibition by St. John's wort constituents hypericin and hyperforin. *J. Pharm. Pharmacol.* 56:123–128.
- WATKINS, P. B. 1997. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. *Adv. Drug Deliv. Rev.* 27:161–170.
- WINDSOR, D., ROUX, S. J., and LLOYD, A. 2003. Multiherbicide tolerance conferred by AtPgpl and apyrase overexpression in *Arabidopsis thaliana*. *Nat. Biotechnol.* 21:428–433.
- YAZAKI, K., SHITAN, N., TAKAMATSU, H., UEDA, K., and SATO, F. 2001. A novel *Coptis japonica* multidrug-resistant protein preferentially expressed in the alkaloid-accumulating rhizome. *J. Exp. Bot.* 52:877–879.
- ZAMORA, J. M., PEARCE, H. L., and BECK, W. T. 1988. Physical–chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. *Mol. Pharmacol.* 33:454–462.
- ZHANG, Y. and BENET, L. Z. 2001. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. *Clin. Pharmacokinet.* 40:159–168.
- ZHOU, S., LIM, L., and CHOWBAY, B. 2004. Herbal modulation of P-glycoprotein. *Drug Metab. Rev.* 36:57–104.